Henan Cao
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Henan Cao has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
- Guiliang Zheng
School of Basic Medical Sciences, Tianjin Medical University, Tianjin 300070, China
1 shared publication - Lingling Chen
School of Basic Medical Sciences, Tianjin Medical University, Tianjin 300070, China
1 shared publication - Shulei Jia
School of Basic Medical Sciences, Tianjin Medical University, Tianjin 300070, China
1 shared publication - Wanying Gao
Institute of EcoHealth, School of Public Health, Cheeloo College of Medicine, Shandong University, Jinan 250012, China
1 shared publication - Xiao Jiang
School of Basic Medical Sciences, Tianjin Medical University, Tianjin 300070, China
1 shared publication - Yang Li
School of Basic Medical Sciences, Tianjin Medical University, Tianjin 300070, China
1 shared publication
Latest Publications
- Open Access
- 2 March 2026
- Published by MDPI AG in Microorganisms
- Vol. 14 (3) , 567
In Silico Design and Characterization of a Multi-Epitope Vaccine Candidate Against Mycoplasma pneumoniae Using a Reverse Vaccinology Strategy
Mycoplasma pneumoniae (M. pneumoniae) is the crucial factor of global acquired respiratory infections. Currently, there are no specific disease modification treatments or vaccines available, and the vaccine development for this pathogen lags behind due to the complexity and variability of its antigens. A novel vaccine with broad-spectrum characteristics is essential to provide comprehensive protection against continuously evolving wild-type strains. Here, a broad-spectrum muti-epitope vaccine against M. pneumoniae had been designed through immunoinformatics methods. To ensure its broad-spectrum, we generated consistent sequences from all the antigen proteins of different strains, and then identified potential T cell epitopes. The multi-epitope vaccine (MEV) of M. pneumoniae incorporated 16 CTLs and 7 HTLs from the HMW1–3 and p1 adhesin proteins, which comprised 458 amino acids with adjuvant. The vaccine evaluation showed that the MEV had ideal physicochemical properties, high antigenicity, high immunogenicity, and was non-toxic. Furthermore, there was a strong and stable binding interaction between this vaccine and the toll-like receptors, which could be supported by the normal mode analysis. Finally, codon optimization resulted in the optimal GC content and higher CAI value. The vaccine candidate is expected to induce strong cellular immune responses and may provide protective immunity against the pathogen. We provided a novel in silico vaccine design strategy for vaccine design, which could provide a technical framework for the development of vaccines against other pathogens.
- 2 March 2026
- Published by MDPI AG in Microorganisms
- Vol. 14 (3) , 567
Open AccessIn Silico Design and Characterization of a Multi-Epitope Vaccine Candidate Against Mycoplasma pneumoniae Using a Reverse Vaccinology Strategy
Mycoplasma pneumoniae (M. pneumoniae) is the crucial factor of global acquired respiratory infections. Currently, there are no specific disease modification treatments or vaccines available, and the vaccine development for this pathogen lags behind due to the complexity and variability of its antigens. A novel vaccine with broad-spectrum characteristics is essential to provide comprehensive protection against continuously evolving wild-type strains. Here, a broad-spectrum muti-epitope vaccine against M. pneumoniae had been designed through immunoinformatics methods. To ensure its broad-spectrum, we generated consistent sequences from all the antigen proteins of different strains, and then identified potential T cell epitopes. The multi-epitope vaccine (MEV) of M. pneumoniae incorporated 16 CTLs and 7 HTLs from the HMW1–3 and p1 adhesin proteins, which comprised 458 amino acids with adjuvant. The vaccine evaluation showed that the MEV had ideal physicochemical properties, high antigenicity, high immunogenicity, and was non-toxic. Furthermore, there was a strong and stable binding interaction between this vaccine and the toll-like receptors, which could be supported by the normal mode analysis. Finally, codon optimization resulted in the optimal GC content and higher CAI value. The vaccine candidate is expected to induce strong cellular immune responses and may provide protective immunity against the pathogen. We provided a novel in silico vaccine design strategy for vaccine design, which could provide a technical framework for the development of vaccines against other pathogens.